Epygen Biotech

Executive Summary

Epygen Biotech is a private biopharmaceutical company headquartered in Cambridge, Massachusetts, with additional operations in India. Founded in 2019, the company specializes in the research, development, and manufacturing of affordable biosimilars and therapeutic proteins targeting oncology, cardiovascular diseases, immune disorders, and vaccines. Leveraging decades of expertise in recombinant protein expression and protein separation, Epygen aims to address the growing global demand for cost-effective biologics. The company operates state-of-the-art facilities in both the US and India, positioning itself as a competitive global player in the biosimilars market. While Epygen has not yet disclosed its pipeline or financial details, its focus on established modalities and cost advantages suggests potential for growth. However, as a private firm with limited public information, the near-term visibility of its progress is restricted.

Upcoming Catalysts (preview)

• Q3 2026FDA filing or acceptance of Investigational New Drug (IND) application for a lead biosimilar candidate50% success
• Q4 2026Expansion of manufacturing capacity at the Indian facility to support commercial-scale production70% success
• 2026Strategic licensing or co-development agreement with a global pharmaceutical company for commercialization in key markets40% success